Nipocalimab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Nipocalimab. Educational only — not medical advice.
Labeled uses
IMAAVY is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Source: FDA labeling via NIH DailyMed (set 8886274c…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.